experimental anti-HER2 triple-targeted therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for experimental anti-HER2 triple-targeted therapy, covering 2025-12-18 to 2025-12-18. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients. [Phase 2]